|
KMID : 1137020190300050086
|
|
Journal of Gynecologic Oncology
2019 Volume.30 No. 5 p.86 ~ p.86
|
|
|
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
|
|
Kok Peey-Sei
Beale Philip
O’Connell Rachel L.
Grant Peter
Bonaventura Tony
Scurry James
Antill Yoland
Goh Jeffrey
Sjoquist Katrin
DeFazio Anna
Mapagu Cristina
Amant Frederic
Friedlander Michael
|
|
|
Abstract
|
|
|
Objective: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER+). PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity of anastrozole in patients with ER+ and/or progesterone receptor (PR)-positive (PR+) recurrent/metastatic gynecological cancers.
Methods: Postmenopausal women with ER+ and/or PR+ ROC, who were asymptomatic and had cancer antigen 125 (CA125) progression after response to first line chemotherapy, where chemotherapy was not clinically indicated. Patients received anastrozole 1 mg daily until progression or unacceptable toxicity.
Results: Fifty-four patients were enrolled (52 evaluable). Clinical benefit at three months (primary endpoint) was observed in 18 patients (34.6%; 95% confidence interval [CI]=23%?48%). Median progression-free survival (PFS) was 2.7 months (95% CI=2.1?3.1). The median duration of clinical benefit was 6.5 months (95% CI=2.8?11.7). Most patients progressed within 6 months of starting anastrozole but 12 (22%) continued treatment for longer than 6 months. Anastrozole was well tolerated. In the exploratory analysis, ER histoscores and the intensity of ER staining did not correlate with clinical benefit rate or PFS.
Conclusion: A subset of asymptomatic patients with ER+ and/or PR+ ROC and CA125 progression had durable clinical benefit on anastrozole, with acceptable toxicity. Anastrozole may delay symptomatic progression and the time to subsequent chemotherapy. The future challenge is to identify the subset of patients most likely to benefit from an aromatase inhibitor and whether the clinical benefit could be increased by the addition of other agents.
|
|
|
KEYWORD
|
|
|
Ovarian Neoplasm, CA-125 Antigen, Estrogens, Aromatase Inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|